Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 50 mcg once daily in COPD (2‑period crossover vs placebo)
2008-006849-28Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: 24-hour bronchodilatory efficacy after 14 days. Started Jan 2009; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-006849-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006849-28.